Innovent, Eli Lilly release results of ORIENT-11 trial for lung cancer

By Nikita Chaurasia  Date: 2020-09-21

Innovent, Eli Lilly release results of ORIENT-11 trial for lung cancer

Innovent Biologics Inc., in collaboration with American pharmaceutical giant Eli Lilly and Company, have reportedly announced that the biomarker results of ORIENT-11 trials which were displayed during a mini verbal presentation at ESMO (European Society for Medical Oncology) Virtual Congress 2020.

As per the credible sources, ORIENT-11 is a phase 3 clinical trial that evaluates TYVYT® combined with ALIMTA® and platinum chemotherapy as a cure for recurrent or advanced nonsquamous non-small cell lung cancer without modifying ALK rearrangements or EGFR mutations.

In fact, the NMPA (National Medical Products Administration) of China has already approved the supplemental New Drug Application (sNDA) for this indication.

If sources are to be believed, data analysis on biomarker showed that MHC-II antigen presentation pathway has played a major role in immunotherapy-chemotherapy combination. Additionally, higher gene expression of this route can serve as a predictive biomarker which allows individuals to choose for whom this regimen can be beneficial.

Head of Department of Internal Medicine at Sun Yat-sen University Cancer Center as well as the primary investigator of the ORIENT-11 trials, Professor Li ZHANG, reportedly stated that there is improvement in efficiency when Sintilimab is combined with pemetrexed and platinum chemotherapy. He further added that there are no newly detected safety signals in nonsquamous metastatic or locally advanced NSCLC.

Dr. Li Wang, Senior VP at Lilly China as well as the Head of Lilly China Drug Development and Medical Affairs Center, claimed that exploring the use of biomarkers helps in effectively understanding cancer immunotherapy.  She further mentioned that the company is thrilled about the results and is looking forward to presenting the results at ESMO.

Reportedly, the primary results on the research were declared in IASLC World Conference on Lung Cancer (WCLC) 2020 Virtual Presidential Symposium in a presentation held verbally and were published by Journal of Thoracic Oncology.

Source credits-

https://www.benzinga.com/pressreleases/20/09/n17577448/innovent-and-lilly-release-biomarker-results-of-tyvyt-sintilimab-injection-in-combination-with-ali

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

1health to offer two types of COVID-19 testing kits to SkyWest Airlines

1health to offer two types of COVID-19 testing kits to SkyWest Airlines

By Nikita Chaurasia

Leading Testing as a Service (TaaS) provider, 1health, recently announced that it has partnered with SkyWest Airlines, a SkyWest Inc. subsidiary, to provide two types of COVID-19 tests to the airline’s personnel. Mehdi Maghsoodnia, CEO at 1hea...

FBI to remove backdoors from hacked Microsoft Exchange email servers

FBI to remove backdoors from hacked Microsoft Exchange email servers

By Nikita Chaurasia

Following the recent cyber-attack in the US, a court in Houston has reportedly authorized a new FBI operation to copy and eliminate backdoors from large number of Microsoft Exchange email servers across the country. During this hacking event, the hac...

France might ban short domestic flights to reduce its carbon footprint

France might ban short domestic flights to reduce its carbon footprint

By Nikita Chaurasia

French lawmakers recently came to a unanimous decision to ban domestic flights for distances that can be covered by train in over two-and-a-half- hours. The country aims to impose these restrictions in an effort to reduce carbon emissions, even as th...

Kavak secures USD 485 million in funding, eyes Latin America expansion

Kavak secures USD 485 million in funding, eyes Latin America expansion

By Nikita Chaurasia

Kavak, a Mexico-based used-car platform, has reportedly reached a valuation of USD 4 billion after securing USD 485 million during a new funding round. This makes it the fastest-growing as well as the most valued company in Latin America. The latest...

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

By Nikita Chaurasia

Indian pharmaceutical company Zydus Cadila is reportedly seeking approval from DCGI (Drug Controller General of India) for its PegIFN (Pegylated Interferon Alpha-2b), a hepatitis C drug, to treat COVID-19 patients, after its third phase of clinical t...